Imidazo[4,5-d]thiazole Compounds Selective IFN-α Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune response modifiers that induce cytokine biosynthesis, particularly interferon-α (IFN-α) and tumor necrosis factor-α (TNF-α), often do so at similar or higher concentrations, leading to unwanted pro-inflammatory effects.
Innovation Solution
Development of 2-(hydroxyalkyl) substituted compounds of Formulas I, II, and III, which preferentially induce IFN-α biosynthesis with significantly reduced TNF-α induction, achieving this through specific chemical structures and administration as pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If immune response modifiers are used to induce cytokine biosynthesis, then interferon-α production is improved, but tumor necrosis factor-α induction increases leading to pro-inflammatory effects
Solution Approach 1:
The patent applies local quality by modifying specific positions (2-position and 3-position) of the imidazo[4,5-d]thiazole core structure with particular substituents (hydroxyalkyl at 2-position, alkyl/alkenyl/alkynyl at 3-position) to create compounds that selectively induce IFN-α while suppressing TNF-α, thereby achieving localized chemical modification for differential cytokine induction
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (hydroxyalkyl, alkyl, alkoxy), chain lengths (n=1-4), and molecular weights to optimize the ratio of IFN-α to TNF-α induction, transforming the chemical structure parameters to achieve selective immunomodulation
2Reliability
If compounds are designed to preferentially induce IFN-α, then therapeutic selectivity is improved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: the imidazo[4,5-d]thiazole core (provides base activity), the 2-position hydroxyalkyl substituent (controls IFN-α selectivity), and the 3-position substituent (modulates TNF-α suppression), allowing independent optimization of each segment for selective cytokine induction
Solution Approach 2:
The patent uses composite materials by combining multiple substituent types (hydroxy, alkyl, alkoxy, halogen) on a single imidazo[4,5-d]thiazole core structure to create composite molecules that achieve both IFN-α induction and TNF-α suppression through synergistic structural features
Data Source
AI summary
A method of preferentially inducing IFN-α biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-α biosynthesis in an animal are disclosed.